Chemomab Therapeutics Past Earnings Performance
Past criteria checks 0/6
Chemomab Therapeutics's earnings have been declining at an average annual rate of -44.6%, while the Biotechs industry saw earnings growing at 15% annually.
Key information
-44.6%
Earnings growth rate
-59.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -145.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Chemomab Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -19 | 6 | 15 |
| 31 Dec 23 | 0 | -24 | 7 | 18 |
| 30 Sep 23 | 0 | -29 | 9 | 21 |
| 30 Jun 23 | 0 | -33 | 11 | 23 |
| 31 Mar 23 | 0 | -31 | 11 | 21 |
| 31 Dec 22 | 0 | -28 | 12 | 17 |
| 30 Sep 22 | 0 | -24 | 11 | 13 |
| 30 Jun 22 | 0 | -19 | 10 | 10 |
| 31 Mar 22 | 0 | -16 | 8 | 8 |
| 31 Dec 21 | 0 | -12 | 6 | 6 |
| 30 Sep 21 | 0 | -9 | 4 | 5 |
| 30 Jun 21 | 0 | -8 | 3 | 5 |
| 31 Mar 21 | 0 | -6 | 2 | 4 |
| 31 Dec 20 | 0 | -6 | 1 | 5 |
| 30 Sep 20 | 0 | 11 | -3 | -3 |
| 31 Dec 19 | 0 | -7 | 1 | 6 |
Quality Earnings: CMMB is currently unprofitable.
Growing Profit Margin: CMMB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CMMB is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare CMMB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CMMB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: CMMB has a negative Return on Equity (-145.05%), as it is currently unprofitable.